At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 79 enrolled
Drug / intervention
AMG 890 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a)
In Brief
A Phase 1 clinical trial evaluating AMG 890 and Placebo for Cardiovascular Disease. Completed, enrolled 79 participants across 9 sites in 2 countries.
Detailed Summary
This is a first-in-human, randomized, double-blind, placebo-controlled, single ascending dose study in subjects with elevated plasma Lipoprotein(a) \[Lp(a)\]. AMG 890 will be evaluated in approximately 80 subjects to assess safety, tolerability, pharmacokinetics and pharmacodynamic effects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCardiovascular Disease
CountriesAustralia, United States
Collaborators--
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
Enrollment StartJul 2018
First PostedAug 2018
Primary CompletionApr 2023
TodayJul 2026
First PostedAug 13, 2018
Enrollment StartJul 30, 2018
Primary CompletionApr 18, 2023
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 7.9 years ago
Interventions
AMG 890drug
Ascending Single Doses of AMG 890
Placebodrug
Calculated volume to match experimental drug.